Older people with HIV Infections and Infestations Human immunodeficiency virus [HIV] disease
Conditions
Interventions
Why this study design and methodology?
Whilst the Silver Clinic is already running and here is where the Comprehensive Geriatric Assessment is carried out, it is not known whether it is better than ‘u
Sponsors
University of Sussex
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Older people with HIV, with evidence of frailty 3+ on the frailty screening, using the Frail scale 2. Consent to contact the GP
Exclusion criteria
Exclusion criteria: 1. Those not defined as frail 2. Attended the Silver Clinic during the last 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of a definitive trial, determined using recruitment rates, completion rates of study outcome measures, and retention at specific timepoints. A priori criteria for trial feasibility are as follows: 1. Recruitment of 20% of eligible patients 2. Recruitment of 84 patients within 3 months from first patient randomised 3. Retention of 70 patients (allowing up to 15% attrition) to primary endpoint (6 months) 4. Outcome measure completion for 90% of available participants at each timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Symptoms and concerns measured using the Positive Outcomes HIV PROM at baseline, week 26 (first follow up) and week 52 (final visit) 2. Quality of life measured using the EuroQol 5D-5L at baseline, week 26 (first follow up) and week 52 (final visit) 3. Social care related quality of life measured using the Adult Social Care Outcomes Toolkit (ASCOT) at baseline, week 26 (first follow up) and week 52 (final visit) 4. Services and support participants have accessed measured using the Client Service Receipt Inventory (CSRI) at baseline, week 26 (first follow up) and week 52 (final visit) 5. Patient-rated experience measure of the interpersonal quality of healthcare encounters measured using the Consultation and relational empathy measure (CARE) at baseline, week 26 (first follow up) and week 52 (final visit) 6. Frailty measured using the Fried Frailty Phenotype measure at baseline, week 26 (first follow up) and week 52 (final visit) 7. Frailty measured using the FRAIL Scale at baseline, week 26 (first follow up) and week 52 (final visit) 8. Functional mobility measured using the Time up and go test at baseline, week 26 (first follow up) and week 52 (final visit) 9. A person's level of vulnerability to poor outcomes, measured using the Rockwood clinical frailty scale at baseline, week 26 (first follow up) and week 52 (final visit) | — |
Countries
United Kingdom
Outcome results
None listed